(Q48718306)

14 February 2018

title

Low values of 5-hydroxymethylcytosine (5hmC), the "sixth base," are associated with anaplasia in human brain tumors (English)

1 reference

14 February 2018

1 reference

14 February 2018

Markus Müller

1 reference

14 February 2018

Thomas Carell

1 reference

14 February 2018

David Widmann

0 references

Ulrich Schüller

0 references

Theo F J Kraus

1 reference

14 February 2018

Mirko Wagner

1 reference

14 February 2018

Sabina Eigenbrod

1 reference

14 February 2018

Martin Münzel

1 reference

14 February 2018

Toni Pfaffeneder

1 reference

14 February 2018

Benjamin Hackner

1 reference

14 February 2018

Wolfgang Feiden

1 reference

14 February 2018

Hans A Kretzschmar

1 reference

14 February 2018

language of work or name

English

0 references

publication date

2 March 2012

1 reference

14 February 2018

International Journal of Cancer

published in

1 reference

14 February 2018

volume

131

1 reference

14 February 2018

issue

1 reference

14 February 2018

page(s)

1577-1590

1 reference

14 February 2018

MGMT gene silencing and benefit from temozolomide in glioblastoma

cites work

1 reference

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents

21 January 2018

1 reference

The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain

21 January 2018

1 reference

Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA

21 January 2018

1 reference

Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine

21 January 2018

1 reference

The discovery of 5-formylcytosine in embryonic stem cell DNA.

21 January 2018

1 reference

Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1

21 January 2018

1 reference

Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells

21 January 2018

1 reference

Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers.

21 January 2018

1 reference

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

Cancer epigenomics: DNA methylomes and histone-modification maps

21 January 2018

1 reference

21 January 2018

Epigenetics in cancer

1 reference

Epigenetic modifications and human disease

21 January 2018

1 reference

Epigenetic gene silencing in cancer: the DNA hypermethylome

21 January 2018

1 reference

Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates

21 January 2018

1 reference

Quantification of the sixth DNA base hydroxymethylcytosine in the brain

21 January 2018

1 reference

Genomic mapping of 5-hydroxymethylcytosine in the human brain

21 January 2018

1 reference

5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations

21 January 2018

1 reference

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

21 January 2018

1 reference

TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.27429

1 reference

14 February 2018

1 reference

14 February 2018